EGFR and renal fibrosis: In 2018, Yamamoto et al. (20) demonstrated that EGFR blocking by erlotinib, a tyrosine kinase inhibitor (TKI) of EGFR, not only protected against renal fibrosis in 5/6-nephrectomized rats but also decreased the inflammation, highlighting the renoprotective effects of this TKI.